ITOS — iTeos Therapeutics Share Price
0.000.00%
Last trade - 00:00- $297.39m
- -$222.98m
- $35.00m
- 71
- 31
- 55
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.53 | ||
| Price to Tang. Book | 0.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.53% | ||
| Return on Equity | -23.68% | ||
| Operating Margin | -435.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 344.77 | 267.63 | 12.6 | 35 | 7.4 | 9.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -54.94 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Directors
- David Hallal NEC (54)
- Michel Detheux CEO (55)
- Matthew Gall CFO (44)
- Matthew Call COO (48)
- Yvonne Mcgrath VRD (47)
- Joanne Lager OTH (49)
- Detlev Biniszkiewicz IND
- Aaron Davis IND (42)
- Derek Di Rocco IND (41)
- Tony Ho IND (55)
- Robert Iannone IND (54)
- Ann Rhoads IND (56)
- Matthew Roden IND (50)
- Tim Van Hauwermeiren IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- October 4th, 2019
- Public Since
- July 24th, 2020
- No. of Shareholders
- 203
- No. of Employees
- 173
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 38,273,795
- Address
- 321 Arsenal Street, WATERTOWN, 02472
- Web
- https://www.iteostherapeutics.com/
- Phone
- +1 8572044583
- Auditors
- Deloitte Bedrijfsrevisoren
Upcoming Events for ITOS
Q2 2025 Iteos Therapeutics Inc Earnings Release
Similar to ITOS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the iTeos Therapeutics share price?
As of Today at 21:24 UTC, shares in iTeos Therapeutics are trading at $7.77. This share price information is delayed by 15 minutes.
How has the iTeos Therapeutics share price performed this year?
Shares in iTeos Therapeutics last closed at $7.77 and the price had moved by -32.38% over the past 365 days. In terms of relative price strength the iTeos Therapeutics share price has underperformed the S&P500 Index by -39.02% over the past year.
What are the analyst and broker recommendations for iTeos Therapeutics?
The overall consensus recommendation for iTeos Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the iTeos Therapeutics dividend yield?
iTeos Therapeutics does not currently pay a dividend.
Does iTeos Therapeutics pay a dividend?
iTeos Therapeutics does not currently pay a dividend.
When does iTeos Therapeutics next pay dividends?
iTeos Therapeutics does not currently pay a dividend.
How do I buy iTeos Therapeutics shares?
To buy shares in iTeos Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of iTeos Therapeutics?
As of the previous close price of $7.77, shares in iTeos Therapeutics had a market capitalisation of $297.39m.
Where are iTeos Therapeutics shares listed?
Here are the trading details for iTeos Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ITOS
What kind of share is iTeos Therapeutics?
Based on an overall assessment of its quality, value and momentum iTeos Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a iTeos Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in iTeos Therapeutics is $25.00. That is 221.75% above the last closing price of $7.77.
Analysts covering iTeos Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.91 for the next financial year.
Find out moreWhat is the trend in the iTeos Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like iTeos Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -11.4%.
As of the last closing price of $7.77, shares in iTeos Therapeutics were trading -20% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the iTeos Therapeutics PE Ratio?
The iTeos Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of iTeos Therapeutics?
iTeos Therapeutics' management team is headed by:
- David Hallal - NEC
- Michel Detheux - CEO
- Matthew Gall - CFO
- Matthew Call - COO
- Yvonne Mcgrath - VRD
- Joanne Lager - OTH
- Detlev Biniszkiewicz - IND
- Aaron Davis - IND
- Derek Di Rocco - IND
- Tony Ho - IND
- Robert Iannone - IND
- Ann Rhoads - IND
- Matthew Roden - IND
- Tim Van Hauwermeiren - IND